| Name | Title | Contact Details |
|---|
Envision Healthcare is on the front lines of change. Through our primary business units – Envision Physician Services, Evolution Health and AMSURG – our clinician-led organization is changing the face of healthcare by delivering high-quality care that elevates the patient experience. Envision Healthcare is pioneering solutions to the toughest challenges in healthcare. We serve as a partner to help navigate the constantly evolving landscape of healthcare delivery, and we are vigilant in working with health systems and hospitals to identify opportunities to better serve our communities. Our physicians, advanced practice providers and support teams are responsible for more than 30 million annual patient encounters across the U.S. Learn more about how we care for patients here.MISSION Our mission is to improve the patient experience and public health while reducing the cost of available healthcare per capita. As the largest provider of physician services to hospital and health systems through Envision Physician Services, we are committed to supporting our hospital and health system partners in delivering local, high-quality care. COMMUNITIES Our employees are committed to supporting the communities we serve by providing charitable donations. Our time is dedicated to helping our communities remain safe, active, healthy and productive by getting involved and giving back.
Saint Francis Health Services is a Morris, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Meridian Heights Afc is a Sault Sainte Marie, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Scilucent is a Herndon, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates. These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending. Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™. The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee. Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema. Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.